Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Opioid Crisis Lawsuits
Pharmalot

Drug maker payments to doctors are linked to higher opioid overdose deaths

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: the latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA will furlough more people; FDA panel is divided over new diabetes drug

By Ed Silverman

Nursing Home Abuse
Pharmalot

Groups opposing Medicare Part D talks are criticized for failing to disclose industry ties

By Ed Silverman

US Capitol dome
Pharmalot

Once again, lawmakers introduce a bill to end tax breaks for consumer drug ads. Will it work this time?

By Ed Silverman

Hospitals-Flu Season-Shortages
Pharmalot

New drug shortages rose in 2018 after three years of relative stability

By Ed Silverman

Pharmalot

A former Pfizer flight attendant wins the right to sue for discrimination, raising questions about arbitration

By Ed Silverman

Pharmalot

Pharmalittle: FDA panel backs Amgen osteoporosis drug; campaign launched to tank a Trump Medicare proposal

By Ed Silverman

Pharmalot

Rising drug prices are making hospitals feel a little sick

By Ed Silverman

FDA; Drug Administration campus
Pharmalot

FDA is urged to mandate disclosure of clinical trial summaries as pilot program stalls

By Ed Silverman

Pharmalot

Pharmalittle: Some FDA employees return to work; Azar defends a plan to change Medicare Part B

By Ed Silverman

AmerisourceBergen
Pharmalot

AmerisourceBergen will eliminate 15 percent of workers at a troubled compounding unit

By Ed Silverman

Chemotherapy infusion
Pharmalot

Trump proposal to shift Part B drugs to Part D would hurt most beneficiaries, analysis says

By Ed Silverman

Pharmalot

Allergan and a Mohawk tribe ask the Supreme Court to review their controversial patent deal

By Ed Silverman

Pharmalot

Pharmalittle: Walmart leaves CVS networks over pricing; EMA to lose 25 percent of its staff due to relocation

By Ed Silverman

Peter Welch
Pharmalot

Lawmakers want feds to look at how a Bristol-Celgene deal affects prices and competition

By Ed Silverman

VA veterans affairs building
Pharmalot

Medicare Part D could have saved $14.4 billion in 2016 by negotiating as the VA did

By Ed Silverman

Novartis International pharmaceutical
Pharmalot

Novartis battles with the Dutch health minister for raising the price of a cancer drug

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: ‘Netflix’ model for hep C drugs proceeds; J&J hikes drug prices

By Elizabeth Cooney

Hep C San Fran
Pharmalot

Louisiana proceeds with plans for a ‘Netflix’ subscription model to buy hepatitis C drugs

By Ed Silverman

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

Pharmalot

Pharmalittle: Biologic makers use scare tactics to ward off biosimilar use; insulin prices are raised

By Ed Silverman

Pharmalot

Pharmalittle: Allergan CEO says ‘social contract’ intact; medical marketing skyrockets to $30 billion

By Elizabeth Cooney

Brent Saunders
Pharma

Allergan CEO: We stuck to the spirit of our social contract with recent price hikes

By Ed Silverman and Matthew Herper

Drug Prices
Pharmalot

California governor moves to bolster negotiating power for lower drug prices

By Ed Silverman

Pharma TV Ad
Pharmalot

Medical marketing exploded over the past two decades, raising questions about industry influence

By Ed Silverman

Pharmalot

Pharmalittle: Existing drugs driving higher prices; Baselga lands at AstraZeneca

By Elizabeth Cooney

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy